publication date: Oct. 5, 2018
Issue 37 - Oct. 5, 2018
TCL44-37 (279 downloads)
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

  • Guest Editorial

    When your harmonica player wins the Nobel Prize

    THE CHECKPOINTS were born in 2007 on an escalator in Chicago. Here’s the story…

    Back then, in an oncology era that we’ll fondly call “The Dark Ages,” no one, except a small gaggle of Don Quixotes, believed that the immune system could cure cancer. Immunotherapy stalwarts (like my friends and I) were such outcasts that our presentations at the American Society of Clinical Oncology annual meeting were scheduled for the last day of the conference (when just about everyone had already gone home) and assigned to a lecture hall that was too remote for anything but sensible shoes.

  • Guest Editorial

    Thank you, Jim Allison

    The year was 1998, location, Italian Alps. Jim and I were attending an intimate Pezcoller meeting organized by David Livingston. At that meeting, Jim presented something I had never seen in the entirety of my career—the eradication of cancer in mice following treatment with an antibody designed to inhibit a T cell checkpoint mechanism.

  • Craig Thompson resigns from two corporate boards as MSK crisis shifts to board roles

    Craig Thompson, president and CEO of Memorial Sloan Kettering Cancer Center, resigned from two corporate boards of directors—the pharmaceutical company Merck & Co., and Charles River Laboratories International Inc., a company focused on early-stage drug development and manufacturing of novel compounds.

  • Conversation with The Cancer Letter

    Roy Jensen: “In general, I think cancer center directors still enjoy a certain amount of respect”

    As the new president of the Association of American Cancer Institutes, Roy Jensen will focus on public policy at the state and local level as his presidential priority.

  • An Appreciation

    Philip DiSaia, former head of Gynecologic Oncology Group, dies at 81

    The grandson of Italian immigrants, Philip John DiSaia was born on Aug. 14, 1937 in Providence, Rhode Island. He earned his Bachelor’s in Science at Brown University and his MD at Tufts University.

  • In Brief

    • Ruth O’Regan named chief scientific officer of Big Ten Cancer Research Consortium
    • Peter Wiklund named director of the Bladder Cancer Program at Mount Sinai
    • 2018 NIH Director’s awards for high-risk, high-reward research program announced
    • Queen’s University Belfast and the University of Leeds researchers win the 2018 European Health Award
    • Shirley Mertz elected chair and Christine Benjamin vice chair of Metastatic Breast Cancer Alliance

  • TCCL Logo

  • Trials & Tribulations

    How tumor-specific modulation frequencies were discovered

    In the spring of 2001, I visited a longtime friend and collaborator, Alexandre Barbault, to share with him my vision of using low levels radiofrequency electromagnetic fields for the treatment of cancer.

  • Clinical Roundup

    • Aspirin lowers risk of ovarian and hepatocellular cancer
    • Genentech’s Entrectinib showed durable response of more than two years NSCLC

  • Drugs & Targets

    • FDA releases draft guidance on master protocol studies
    • FDA approves Kyprolis with dexamethasone for relapsed or refractory multiple myeloma
    • FDA authorizes first next-gen sequencing-based test in patients with ALL, MM
    • FDA approves Libtayo as first and only treatment for advanced CSCC

Copyright (c) 2018 The Cancer Letter Inc.

Back to top